Insights

Gathering insights about Apto…

Similar companies to Apto

Apto Tech Stack

Apto uses 8 technology products and services including Criteo, Google Analytics Enhanced eCommerce, Hotjar, and more. Explore Apto's tech stack below.

Criteo
Advertising
Google Analytics Enhanced eCommerce
Analytics
Hotjar
Analytics
cdnjs
Content Delivery Network
Cloudflare
Content Management System
Webpack
Development
Google Sign-in
Identity Verification
SweetAlert
Javascript Libraries

Media & News

Why Is Penny Stock Aptose Biosciences Trading Higher On Thursday?
On Thursday, Aptose Biosciences Inc. APTO announced that the Cohort Safety Review Committee monitoring Phase 1/2 TUSCANY trial of tuspetinib in combination with standard of care dosing of venetoclax and azacitidine (TUS+VEN+AZA triplet) has approved escalating from 40 mg TUS to 80 mg TUS based on its favorable review of data from the first four patients in the trial.
Feb 20, 2025 | www.benzinga.com
Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort
Aptose Announces Positive Clinical Safety Review and Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib
Feb 20, 2025 | www.globenewswire.com
Aptose Announces Reverse Share Split
SAN DIEGO and TORONTO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed AML, today announced that its board of directors (the “Board”) has approved, subject to required regulatory and stock exchange approvals, a plan to consolidate all of its outstanding common shares (the “Common Shares”) on the basis of 1 Common Share for every 30 Common Shares currently outstanding (the "Reverse Share Split"). The Company expects the Reverse Share Split to restore compliance with the minimum bid price requirement set out in Nasdaq Listing Rule 5550(a)(2) and to ensure the Company continues to have access to a wide range of investors.
Feb 18, 2025 | www.globenewswire.com
Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility
SAN DIEGO and TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed AML, today announced it has entered into a common share purchase agreement and registration rights agreement with an institutional investor. The Committed Equity Facility agreement provides Aptose the right, in its sole option and discretion without obligation, to sell and issue up to $25 million of its common shares (the “Common Shares”) over the course of 24 months to the Investor, subject to certain conditions being met, and subject to certain limitations and conditions imposed by the Nasdaq Capital Market (“Nasdaq”), the U.S. Securities and Exchange Commission (the “SEC”) and other regulators.
Feb 13, 2025 | www.globenewswire.com
Aptose's Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial
TUS+VEN+AZA triplet achieves Cycle 1 complete remission (CR) in TP53-mutated/CK AML TUS+VEN+AZA triplet achieves Cycle 1 complete remissions in FLT3-wildtype AML patients TUS+VEN+AZA triplet shows favorable safety with no alteration of VEN and AZA dosing PK levels of TUS in the triplet remain equivalent to levels as TUS or TUS+VEN therapy SAN DIEGO and TORONTO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company, today reported promising early safety and response results from newly diagnosed acute myeloid leukemia (AML) patients dosed in Aptose's Phase 1/2 TUSCANY trial with a 40 mg dose of tuspetinib in combination with standard of care dosing of venetoclax and azacitidine (TUS+VEN+AZA triplet). The TUS+VEN+AZA triplet is being developed as a frontline therapy to treat large, mutationally diverse populations of newly diagnosed AML patients who are ineligible to receive induction chemotherapy.
Feb 12, 2025 | www.globenewswire.com
Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
SAN DIEGO and TORONTO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company, today announced dosing the first set of patients in the TUSCANY Phase 1/2 study with tuspetinib (TUS) in combination with venetoclax (VEN) and azacitidine (AZA) as a frontline triple drug combination (triplet) therapy for patients newly diagnosed with acute myeloid leukemia, or AML. Tuspetinib based TUS+VEN+AZA triplet therapy is being advanced in the TUSCANY Phase 1/2 trial with the goal of creating an improved frontline therapy for newly diagnosed AML patients that is active across diverse AML populations, durable, and well tolerated.
Jan 09, 2025 | www.globenewswire.com
Aptose Announces Positive Decision by Nasdaq Hearings Panel
SAN DIEGO and TORONTO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today announced that the Nasdaq Hearings Panel (“Panel”) has granted the Company's request for an extension to evidence compliance with all applicable criteria for continued listing on The Nasdaq Stock Market. On or before March 31, 2025, the Company will be required to demonstrate compliance with NASDAQ Listing Rule 5550(b)(1) requiring the Company to have a minimum of $2.5 million in shareholders' equity (the “Equity Rule”) and NASDAQ Listing Rule 5550(a)(2) requiring the Company to have a minimum bid price of $1.00 (the “Minimum Bid Price Rule”).
Dec 19, 2024 | www.globenewswire.com

Apto's Email Address Formats

Apto uses at least 1 format(s):

Apto Email Formats	Example	Percentage
First.Last@apto.vc	John.Doe@apto.vc	50%
First.Last@apto.vc	John.Doe@apto.vc	50%

Frequently Asked Questions

Where is Apto's headquarters located?

Apto's main headquarters is located at Av. Dr. Cardoso de Melo, 878 6º andar São Paulo, SP 04548-003 BR. The company has employees across 3 continents, including South AmericaEuropeNorth America.

What is Apto's stock symbol?

Apto is a publicly traded company; the company's stock symbol is APTO.

What is Apto's official website and social media links?

Apto's official website is apto.vc and has social profiles on LinkedIn.

How many employees does Apto have currently?

As of October 2022, Apto has approximately 48 employees across 3 continents, including South AmericaEuropeNorth America. Key team members include Founder & Ceo: A. F.Growth Marketing Manager: A. R.Team Leader De Produtos Digitais E Branding: A. Z.. Explore Apto's employee directory with LeadIQ.

What industry does Apto belong to?

Apto operates in the Technology, Information and Internet industry.

What technology does Apto use?

Apto's tech stack includes CriteoGoogle Analytics Enhanced eCommerceHotjarcdnjsCloudflareWebpackGoogle Sign-inSweetAlert.

What is Apto's email format?

Apto's email format typically follows the pattern of . Find more Apto email formats with LeadIQ.

When was Apto founded?

Apto was founded in 2015.

Apto

Technology, Information and InternetSão Paulo, Brazil11-50 Employees

O Apto representa o rejuvenescimento do mercado imobiliário. Reconstruímos do zero a forma como você busca e decide a compra de um imóvel novo, de uma vez por todas. Viemos para ajudar você a escolher o melhor imóvel possível e tornar esse momento uma experiência excepcional, afinal é a compra da sua vida.

Company Overview

Headquarters: Av. Dr. Cardoso de Melo, 878 6º andar São Paulo, SP 04548-003 BR
Website: apto.vc
Stock Symbol: APTO
Founded: 2015
Employees: 11-50